Journal Reviews
Reclassifying genetic variants in inherited retinal diseases
The authors present a retrospective study of 142 gene sequence variants from 28 patients with vitreoretinal dystrophies which were re-interpreted based on American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines. Overall, there was...
Clinical characteristics and visual outcome of patients with macular pseudohole
This is a retrospective study of consecutive patients with macular pseudohole (MPH) who had vitrectomy and were followed for at least 6 months postoperatively. MPH was diagnosed based on spectral-domain optical coherence tomography (OCT) findings. 76 eyes of 75 patients...
Patient perspectives on inherited retinal diseases
The authors present a qualitative study of patient perspectives on living with inherited retinal diseases based on social media engagement. Social media posts from 6 sites were analysed over a 10-year period. Data was extracted manually by the research team,...
Comparison of the efficacy of anti-VEGFs agents in nvAMD
This retrospective multicentric study conducted in Israel and Canada, compared the efficacy of bevacizumab, aflibercept 2mg and ranibizumab as first-line treatments for neovascular age-related macular degeneration (nvAMD). Included were treatment-naïve nvAMD eyes receiving ≥12 months of treat-and-extend (T&E) anti-VEGF therapy...
Fenofibrate and diabetic retinopathy
Fenofibrate is an agonist of peroxisome proliferator-activated receptor-alpha (PPARα) which is used as a lipid-lowering agent. By reducing blood lipid levels, it can decrease retinal hard exudates which is beneficial in diabetic retinopathy (DR). FIELD and ACCORD studies show that...
IVT Aflibercept 2mg in nAMD: XTEND at 3 years
This study investigated the long-term, effectiveness and safety of IVT-AFL 2mg for neovascular age-related macular degeneration (nAMD). XTEND was a multicentre, observational, prospective study, which was conducted across 127 centres across 17 countries with a follow-up period of 36 months....
ILM peeling in proliferative diabetic retinopathy: a meta-analysis
This meta-analysis highlights the efficacy of internal limiting membrane (ILM) peeling on treating posterior segment complications other than macular oedema in patients with proliferative diabetic retinopathy (PDR) treated with vitrectomy. PubMed, EMBASE and Cochrane Library were searched for databases. Eleven...
Usher syndrome patient reported outcomes
The authors present a systematic review of the literature on patient-reported outcomes in Usher syndrome; a leading cause of deaf-blindness. A total of 27 studies were included, and there was a strong bias towards studies from the US and Europe...
Anti-VEGF injections and macular atrophy progression in patients with nAMD in remission
This is a retrospective study of 59 eyes with neovascuar age-related macular degeneration (nAMD) with at least 6-month remission, to determine the effect of continuing anti-VEGF injections on the progression of macular atrophy (MA) during remission of nAMD. Group 1...
Outcome of patients undergoing immediate sequential bilateral vitreoretinal surgery
This was a multicentre retrospective review of a case series from patients undergoing immediate sequential bilateral vitreoretinal surgery (ISBVS). A proforma was circulated to ophthalmic surgeons across the UK for cases of this rarely performed approach to collate indications, operative...
Use of immunomodulatory treatment for non-infectious uveitis: an International
Two-hundred-and-twenty-one group members from 53 countries completed a questionnaire on their indications, investigations and use of conventional and biologics and follow-up of treated patients. Main indications to start systemic immunomodulatory drugs were: uveitis not controlled by oral prednisolone (94.1%), specific...
AI-Based devices in national screening programmes: barriers and challenges
Diabetic retinopathy (DR) may have long-term complications and is recorded as a leading cause of blindness. National DR screening programmes have effectively reduced severe visual loss by timely detection and subsequent treatment of sight-threatening proliferative DR and diabetic macular oedema....
